The analysis of CD79B expression and clinicopathological factors demonstrated that CD79B expression was related to primary therapy outcome, race, histological type, the degree of differentiation, disease-specific survival, and progression-free interval, whereas there was no statistically significant correlation between CD79B expression and age, tumor depth, distant metastasis, lymph node metastasis, clinical stage, histologic grade, radiation therapy, orBMI. The gene discussed is CD79B; the disease is metastasis.